 Connection
Michael Verneris to Leukemia, Myelogenous, Chronic, BCR-ABL Positive
This is a "connection" page, showing publications Michael Verneris has written about Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.450 |
|
|
|
-
Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. Bone Marrow Transplant. 2009 Aug; 44(3):169-74.
Score: 0.302
-
Verneris MR, Tuel L, Seibel NL. Pediatric HIV infection and chronic myelogenous leukemia. Pediatr AIDS HIV Infect. 1995 Oct; 6(5):292-4.
Score: 0.120
-
Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, Guethlein LA, Trachtenberg EA, Haagenson M, Horowitz MM, Klein JP, Weisdorf DJ. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007 Jun 01; 109(11):5058-61.
Score: 0.016
-
Schrier SL, Centis F, Verneris M, Ma L, Angelucci E. The role of oxidant injury in the pathophysiology of human thalassemias. Redox Rep. 2003; 8(5):241-5.
Score: 0.012
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|